000285813 001__ 285813
000285813 005__ 20260401143002.0
000285813 0247_ $$2doi$$a10.1080/17469899.2025.2563196
000285813 0247_ $$2ISSN$$a1746-9899
000285813 0247_ $$2ISSN$$a1746-9902
000285813 037__ $$aDZNE-2026-00349
000285813 082__ $$a610
000285813 1001_ $$aYu-Wai-Man, Patrick$$b0
000285813 245__ $$aIdebenone as a treatment for Leber hereditary optic neuropathy: A plain language summary of the LEROS study publication
000285813 260__ $$aAbingdon$$bTaylor & Francis Group$$c2025
000285813 3367_ $$2DRIVER$$aarticle
000285813 3367_ $$2DataCite$$aOutput Types/Journal article
000285813 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1775046347_19920$$xEditorial
000285813 3367_ $$2BibTeX$$aARTICLE
000285813 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285813 3367_ $$00$$2EndNote$$aJournal Article
000285813 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285813 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000285813 7001_ $$aNewman, Nancy J.$$b1
000285813 7001_ $$aPoincenot, Lissa$$b2
000285813 7001_ $$aFerguson, James$$b3
000285813 7001_ $$0P:(DE-2719)2810704$$aKlopstock, Thomas$$b4$$eLast author$$udzne
000285813 773__ $$0PERI:(DE-600)2261704-8$$a10.1080/17469899.2025.2563196$$gVol. 20, no. 6, p. 333 - 350$$n6$$p333 - 350$$tExpert review of ophthalmology$$v20$$x1746-9899$$y2025
000285813 7870_ $$0DZNE-2024-00303$$aYu-Wai-Man, Patrick et.al.$$dMaryland Heights, MO : Elsevier, 2024$$iRelatedTo$$r$$tTherapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial.
000285813 8564_ $$uhttps://pub.dzne.de/record/285813/files/DZNE-2026-00349.pdf$$yRestricted
000285813 8564_ $$uhttps://pub.dzne.de/record/285813/files/DZNE-2026-00349.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285813 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810704$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000285813 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285813 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-05
000285813 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2025-11-05
000285813 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-05
000285813 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEXPERT REV OPHTHALMO : 2022$$d2025-11-05
000285813 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-05
000285813 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-05
000285813 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-11-05
000285813 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000285813 980__ $$ajournal
000285813 980__ $$aEDITORS
000285813 980__ $$aVDBINPRINT
000285813 980__ $$aI:(DE-2719)1111015
000285813 980__ $$aUNRESTRICTED